Krystal Biotech reports Q3 2026 financial results
Krystal Biotech reported $127.3 million in VYJUVEK revenue and an $1.2 billion cash balance. The company saw share repurchases and announced ongoing pricing negotiations in Germany and Italy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed